Canada markets closed

Curis, Inc. (CRIS)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
11.20+0.06 (+0.54%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close11.14
Open11.14
Bid0.00 x 0
Ask11.37 x 100
Day's Range11.14 - 11.38
52 Week Range0.38 - 17.49
Volume7,934
Avg. Volume26,869
Market Cap66.014M
Beta (5Y Monthly)3.59
PE Ratio (TTM)N/A
EPS (TTM)-8.62
Earnings DateAug 01, 2024 - Aug 05, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
  • PR Newswire

    Curis Announces Additional Data from TakeAim Leukemia Study

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from the ongoing TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) AML to be presented at the ASCO and EHA conferences.

  • PR Newswire

    Curis to Present Updated Data from the TakeAim Leukemia Study

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will present updated data from the TakeAim Leukemia study Tuesday, May 14, 2024, at 4:00 p.m. ET. Management will host a conference call on the same day at 4:30 p.m. ET.

  • Insider Monkey

    Curis, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call Transcript

    Curis, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call Transcript May 7, 2024 Curis, Inc. misses on earnings expectations. Reported EPS is $-2.0534 EPS, expectations were $-1.94. CRIS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and […]